We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+6.19%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$28.9B
AUM Growth
-$1.88B
(-6.1%)
Cap. Flow
-$3.11B
Cap. Flow
% of AUM
-10.73%
Top 10 Holdings %
Top 10 Hldgs %
36.76%
Holding
1,184
New
80
Increased
351
Reduced
700
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$122M |
| 2 |
NXP Semiconductors
NXPI
|
+$97M |
| 3 |
NVIDIA
NVDA
|
+$42.8M |
| 4 |
VanEck Gold Miners ETF
GDX
|
+$42.2M |
| 5 |
VanEck Junior Gold Miners ETF
GDXJ
|
+$41.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.04B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$547M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$387M |
| 4 |
Intel
INTC
|
+$158M |
| 5 |
Advanced Micro Devices
AMD
|
+$145M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 48.55% |
| 2 | Financials | 9.72% |
| 3 | Consumer Discretionary | 5.52% |
| 4 | Healthcare | 4.26% |
| 5 | Communication Services | 3.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1051
Royalty Pharma
RPRX
$25.9B
| $236K | ﹤0.01% |
6,112
+135
| +2% | +$5.15K |
|
1052
Tarsus Pharmaceuticals
TARS
$2.58B
| $235K | ﹤0.01% |
2,875
-1,105
| -28% | -$82.5K |
|
1053
Prestige Consumer Healthcare
PBH
$2.38B
| $235K | ﹤0.01% |
3,810
+485
| +15% | +$29.7K |
|
|
AVDL
1054
DELISTED
Avadel Pharmaceuticals
AVDL
| $235K | ﹤0.01% |
10,884
+158
| +1% | +$3.07K |
|
1055
Ambarella
AMBA
$3.77B
| $234K | ﹤0.01% |
+3,310
| New | +$267K |
|
1056
Fidelity National Financial
FNF
$13.9B
| $234K | ﹤0.01% |
4,283
-130
| -3% | -$7.4K |
|
1057
Organon & Co
OGN
$3.56B
| $233K | ﹤0.01% |
32,562
+11,485
| +54% | +$90.7K |
|
1058
Alcoa
AA
$11.9B
| $231K | ﹤0.01% |
+4,352
| New | +$178K |
|
1059
nCino
NCNO
$2.02B
| $230K | ﹤0.01% |
+8,982
| New | +$228K |
|
1060
Phathom Pharmaceuticals
PHAT
$708M
| $230K | ﹤0.01% |
+13,855
| New | +$198K |
|
1061
Equitable Holdings
EQH
$13B
| $229K | ﹤0.01% |
4,815
-360
| -7% | -$17.1K |
|
1062
Graco
GGG
$12.9B
| $228K | ﹤0.01% |
2,786
-77
| -3% | -$6.34K |
|
1063
Harrow
HROW
$1.45B
| $228K | ﹤0.01% |
4,657
+86
| +2% | +$3.61K |
|
1064
Innoviva
INVA
$1.55B
| $227K | ﹤0.01% |
11,339
+983
| +9% | +$19.2K |
|
1065
Crinetics Pharmaceuticals
CRNX
$8.84B
| $226K | ﹤0.01% |
4,865
-1,314
| -21% | -$58.5K |
|
|
HUT
1066
Hut 8
HUT
$12.1B
| $226K | ﹤0.01% |
+4,924
| New | +$217K |
|
|
ESPR
1067
DELISTED
Esperion Therapeutics
ESPR
| $226K | ﹤0.01% |
61,045
+32,794
| +116% | +$106K |
|
1068
ANI Pharmaceuticals
ANIP
$1.8B
| $225K | ﹤0.01% |
2,851
+632
| +28% | +$54.7K |
|
1069
Reinsurance Group of America
RGA
$15.5B
| $225K | ﹤0.01% |
1,104
-38
| -3% | -$7.35K |
|
1070
Carlisle Companies
CSL
$14.3B
| $224K | ﹤0.01% |
701
-36
| -5% | -$11.7K |
|
1071
RPM International
RPM
$13.7B
| $224K | ﹤0.01% |
2,155
-63
| -3% | -$6.82K |
|
1072
MasTec
MTZ
$21.1B
| $224K | ﹤0.01% |
1,031
-28
| -3% | -$5.88K |
|
1073
Harmony Biosciences
HRMY
$2.04B
| $223K | ﹤0.01% |
+5,954
| New | +$196K |
|
1074
Lincoln Electric
LECO
$14.2B
| $222K | ﹤0.01% |
925
-28
| -3% | -$6.63K |
|
1075
Collegium Pharmaceutical
COLL
$1.15B
| $222K | ﹤0.01% |
+4,785
| New | +$200K |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q4 2025 Portfolio in Review
As of Q4 2025, Rafferty Asset Management held 1,184 positions worth $28.9B, down 6.1% from $30.8B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Rafferty Asset Management withdrew a net $3.11B in Q4 2025, closing 51 positions and reducing 700 holdings. Its most notable exit was GlobalFoundries, an estimated $13.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 49% of assets, up from 45% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Rafferty Asset Management opened a new position in Ferrovial N.V. Ordinary Shares worth $11.9M.
- Rafferty Asset Management's largest Q4 2025 buy was Ferrovial N.V. Ordinary Shares: 186,539 shares worth $11.9M.
- Rafferty Asset Management added most to Meta Platforms (Facebook) in Q4 2025, an estimated $122M increase.
- Rafferty Asset Management's biggest Q4 2025 reduction was Tesla, cutting an estimated $1.04B.
- Rafferty Asset Management fully exited GlobalFoundries in Q4 2025, selling an estimated $13.3M.
- Rafferty Asset Management's ten largest holdings make up 37% of its $28.9B portfolio in Q4 2025.
- Rafferty Asset Management opened 80 new positions and closed 51 in Q4 2025.
- Rafferty Asset Management's portfolio value fell 6.1% quarter-over-quarter to $28.9B.
Based on Rafferty Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.